<unk>  (INN) (developmental code name ZK-35973) is a steroidal antimineralocorticoid of the spirolactone group that was never marketed.<unk>  possesses 5–8 times the antimineralocorticoid activity of spironolactone in animal studies. The initial discovery of<unk>  was deemed a great success, as no compound with greater antimineralocorticoid activity had been developed since spironolactone in 1957. Moreover,<unk>  itself has virtually no affinity for the androgen receptor while its progestogenic activity shows species differences, being somewhat greater than that of spironolactone in rabbits but absent in mice and rats. As such, it was characterized as a highly potent antimineralocorticoid with far fewer hormonal side effects relative to spironolactone. In clinical trials,<unk>  was found to be 4- to 10-fold as potent as spironolactone as an antimineralocorticoid, and is said to be the most active antimineralocorticoid identified to date. However, it was serendipitously and unexpectedly found that low doses of<unk>  lowered testosterone levels in men during clinical studies. This was determined to be due to metabolic conversion of<unk>  into drospirenone (1,2-dihydrospirorenone) by the enzyme Δ1-hydrase, a transformation that occurs only in monkeys and humans. Unlike<unk> , drospirenone was found to be a highly potent progestin and antiandrogen in addition to antimineralocorticoid, with 8-fold the potency of spironolactone as an antimineralocorticoid and 0.3 times the potency of cyproterone acetate as an antiandrogen. Subsequently, investigation of<unk>  was discontinued and drospirenone was developed and eventually introduced instead as a contraceptive.
Spirorenone
Canrenone
Eplerenone
Cyclothiazide
Chlorothiazide
Olmesartan
Telmisartan
Spironolactone